TY - JOUR
T1 - Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease
AU - CRIC Investigators
AU - Chen, Jing
AU - Budoff, Matthew J.
AU - Reilly, Muredach P.
AU - Yang, Wei
AU - Rosas, Sylvia E.
AU - Rahman, Mahboob
AU - Zhang, Xiaoming
AU - Roy, Jason A.
AU - Lustigova, Eva
AU - Nessel, Lisa
AU - Ford, Virginia
AU - Raj, Dominic
AU - Porter, Anna C.
AU - Soliman, Elsayed Z.
AU - Wright, Jackson T.
AU - Wolf, Myles
AU - He, Jiang
AU - Appel, Lawrence J.
AU - Feldman, Harold I.
AU - Go, Alan S.
AU - Kusek, John W.
AU - Lash, James P.
AU - Ojo, Akinlolu
AU - Townsend, Raymond R.
N1 - Funding Information:
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Budoff reported receiving grants from the National Institutes of Health and General Electric. Dr Rahman reported receiving grants from the National Institutes of Health. Ms Nessel reported receiving funding from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr Wolf reported serving as a consultant to Amgen, Ardelyx, Diasorin, Lilly, Pfizer, Ultragenyx, Amag, Keryx, Sanofi, Incyte, and ZS; receiving grants from the National Institutes of Health and Shire; receiving payment for lectures from Sanofi; having an institutional patent pending; and owning stock in Keryx. No other disclosures were reported.
Funding Information:
Funding/Support: Funding for the Chronic Renal Insufficiency Cohort (CRIC) study was obtained under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). This study also was supported in part by clinical and translational science awards from the National Institutes of Health and the National Center for Advancing Translational Sciences (UL1TR000003 awarded to the Perelman School of Medicine, University of Pennsylvania; UL1TR-000424 awarded to Johns Hopkins University; GCRC M01 RR-16500 awarded to the University of Maryland; UL1TR000439 awarded to the Clinical and Translational Science Collaborative of Cleveland; UL1TR000433 awarded to the Michigan Institute for Clinical and Health Research; UL1RR029879 awarded to the University of Illinois, Chicago; P20 GM109036 awarded to the Center of Biomedical Research Excellence, Tulane University; and UCSF-CTSI UL1 RR-024131 awarded to Kaiser Permanente).
Publisher Copyright:
© 2017 American Medical Association. All rights reserved.
PY - 2017/6
Y1 - 2017/6
N2 - Importance: Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this population. Objective: To study the prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dialysis-naive patients with CKD. Design, Setting, and Participants: The prospective Chronic Renal Insufficiency Cohort study recruited adults with an estimated glomerular filtration rate of 20 to 70 mL/min/1.73m2 from 7 clinical centers in the United States. There were 1541 participants without cardiovascular disease at baseline who had CAC scores. Exposures: Coronary artery calcification was assessed using electron-beam or multidetector computed tomography. Main Outcomes and Measures: Incidence of cardiovascular disease (including myocardial infarction, heart failure, and stroke) and all-cause mortality were reported every 6 months and confirmed by medical record adjudication. Results: During an average follow-up of 5.9 years in 1541 participants aged 21 to 74 years, there were 188 cardiovascular disease events (60 cases of myocardial infarction, 120 heart failures, and 27 strokes; patients may have had >1 event) and 137 all-cause deaths. In Cox proportional hazards models adjusted for age, sex, race, clinical site, education level, physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, use of antihypertensive treatment, current cigarette smoking, diabetes status, body mass index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth factor 23 level, estimated glomerular filtration rate, and proteinuria, the hazard ratios associated with per 1 SD log of CAC were 1.40 (95% CI, 1.16-1.69; P < .001) for cardiovascular disease, 1.44 (95% CI, 1.02-2.02; P = .04) formyocardial infarction, 1.39 (95%CI, 1.10-1.76; P = .006) for heart failure, and 1.19 (95%CI, 0.94-1.51; P = .15) for all-cause mortality. In addition, inclusion of CAC score led to an increase in the C statistic of 0.02 (95%CI, 0-0.09; P < .001) for predicting cardiovascular disease over use of all the above-mentioned established and novel cardiovascular disease risk factors. Conclusions and Relevance: Coronary artery calcification is independently and significantly related to the risks of cardiovascular disease, myocardial infarction, and heart failure in patients with CKD. In addition, CAC improves risk prediction for cardiovascular disease, myocardial infarction, and heart failure over use of established and novel cardiovascular disease risk factors among patients with CKD; however, the changes in the C statistic are small.
AB - Importance: Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortality in this population. Objective: To study the prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dialysis-naive patients with CKD. Design, Setting, and Participants: The prospective Chronic Renal Insufficiency Cohort study recruited adults with an estimated glomerular filtration rate of 20 to 70 mL/min/1.73m2 from 7 clinical centers in the United States. There were 1541 participants without cardiovascular disease at baseline who had CAC scores. Exposures: Coronary artery calcification was assessed using electron-beam or multidetector computed tomography. Main Outcomes and Measures: Incidence of cardiovascular disease (including myocardial infarction, heart failure, and stroke) and all-cause mortality were reported every 6 months and confirmed by medical record adjudication. Results: During an average follow-up of 5.9 years in 1541 participants aged 21 to 74 years, there were 188 cardiovascular disease events (60 cases of myocardial infarction, 120 heart failures, and 27 strokes; patients may have had >1 event) and 137 all-cause deaths. In Cox proportional hazards models adjusted for age, sex, race, clinical site, education level, physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, use of antihypertensive treatment, current cigarette smoking, diabetes status, body mass index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth factor 23 level, estimated glomerular filtration rate, and proteinuria, the hazard ratios associated with per 1 SD log of CAC were 1.40 (95% CI, 1.16-1.69; P < .001) for cardiovascular disease, 1.44 (95% CI, 1.02-2.02; P = .04) formyocardial infarction, 1.39 (95%CI, 1.10-1.76; P = .006) for heart failure, and 1.19 (95%CI, 0.94-1.51; P = .15) for all-cause mortality. In addition, inclusion of CAC score led to an increase in the C statistic of 0.02 (95%CI, 0-0.09; P < .001) for predicting cardiovascular disease over use of all the above-mentioned established and novel cardiovascular disease risk factors. Conclusions and Relevance: Coronary artery calcification is independently and significantly related to the risks of cardiovascular disease, myocardial infarction, and heart failure in patients with CKD. In addition, CAC improves risk prediction for cardiovascular disease, myocardial infarction, and heart failure over use of established and novel cardiovascular disease risk factors among patients with CKD; however, the changes in the C statistic are small.
UR - http://www.scopus.com/inward/record.url?scp=85020559036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020559036&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2017.0363
DO - 10.1001/jamacardio.2017.0363
M3 - Review article
C2 - 28329057
AN - SCOPUS:85020559036
SN - 2380-6583
VL - 2
SP - 635
EP - 643
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 6
ER -